NEW YORK, July 16, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (LUCD) (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of ...

Noridian's foundational LCD, to become effective May 28, 2023, closely aligns with the LCD recently published by the MolDx Program Lucid remains focused on securing clinical utility data and ...

MTF Biologics' AmnioBand® Membrane and AlloPatch® Pliable are among the 18 tissues that will be covered under the newly updated Medicare Local Coverage Determinations (LCDs) for skin substitute grafts ...

Days after revealing them, regulators withdrew new coverage determinations for skin substitutes used to treat diabetic foot and venous leg ulcers.

MOUNTAIN VIEW, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and ...

The Centers for Medicare & Medicaid Services (CMS) uses coverage determinations to decide how Medicare should cover treatments, services, and items. These rules usually apply nationwide. The CMS ...

The Centers for Medicare & Medicaid Services (CMS) uses national coverage determinations to determine how it should cover all treatments, services, and items. The CMS makes national coverage ...

MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test PR Newswire NEW YORK, July 16, 2025 Virtual public CAC meeting ...